Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (<scp>NIC‐ESCC2019</scp>): A multicenter, phase 2 study

Liu, Jun; Li, Jingpei; Lin, Wanli; Шао, Ди; Depypere, Lieven; Zhang, Zhifeng; Li, Zhuoyi; Cui, Fei; Du, Ze-Sen; Zeng, Yuan; Jiang, Shunjun; He, Ping; Gu, Xia; Chen, Huai; Zhang, Hai; Lin, Xiaowei; Huang, Haoda; Lv, Wenqiang; Cai, Wei-Ming; Liang, Wenhua; Liang, Hengrui; Jiang, Wenxi; Wang, Wei; Xu, Ke; Cai, Weipeng; Wu, Kui; Lerut, Toni; Fu, Junhui; He, Jianxing

doi:10.1002/ijc.33976

Public

Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study

Published in International Journal of Cancer • Feb 21, 2022

Authors:

Jun Liu

Jingpei Li

Wanli Lin

Abstract

Abstract Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is controversial, especially in the context of potential benefit of combining PD‐1 blockade with neoadjuvant therapy. This phase 2 study aimed to assess neoadjuvant camrelizumab plus chemotherapy in this population. ...

Subject

Medicine

Chemotherapy

Esophageal squamous cell carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!